HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Phase I study of eptifibatide in patients with sickle cell anaemia.

Abstract
The alphaIIbbeta3 antagonist eptifibatide is an effective treatment for patients with acute coronary syndromes (ACS). Platelet reactivity and CD40 ligand (CD40L) may play a role in the pathophysiology of sickle cell anaemia (SCA) similar to that in ACS, suggesting that inhibition of platelet aggregation and CD40L release by eptifibatide may benefit patients with SCA. Following eptifibatide infusion, safety and pharmacodynamic data were obtained from four SCA patients in their non-crisis, steady states. Eptifibatide was well tolerated, with no adverse changes in the haematological, biochemical or coagulation parameters studied. Eptifibatide did not increase plasma levels of platelet factor 4 or beta-thromboglobulin, P-selectin exposure or platelet:leucocyte aggregate formation. Moreover, decreases in platelet aggregation and soluble CD40L (sCD40L) levels achieved in SCA patients were comparable to those observed in the treatment of ACS. Finally, indicators of inflammation, macrophage inflammatory protein-1alpha, tumour necrosis factor-alpha and myoglobin were reduced following eptifibatide infusion, while vasodilation correlatives, matrix metalloproteinases (MMP-2 and MMP-9) and leptin were increased. Based on these phase I results, eptifibatide may benefit SCA patients by inhibiting platelet aggregation, decreasing sCD40L levels and favourably altering plasma levels of inflammatory mediators.
AuthorsSheritha P Lee, Kenneth I Ataga, Mohamed Zayed, Jeanne M Manganello, Eugene P Orringer, David R Phillips, Leslie V Parise
JournalBritish journal of haematology (Br J Haematol) Vol. 139 Issue 4 Pg. 612-20 (Nov 2007) ISSN: 1365-2141 [Electronic] England
PMID17916103 (Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, CD40
  • Cytokines
  • GDF15 protein, human
  • Growth Differentiation Factor 15
  • Peptides
  • Platelet Aggregation Inhibitors
  • eptifibatide
  • Matrix Metalloproteinases
Topics
  • Adult
  • Anemia, Sickle Cell (drug therapy)
  • Antigens, CD40 (metabolism)
  • Blood Platelets (drug effects)
  • Cytokines (metabolism)
  • Growth Differentiation Factor 15
  • Humans
  • Leukocytes (drug effects)
  • Male
  • Matrix Metalloproteinases (metabolism)
  • Peptides (therapeutic use)
  • Platelet Aggregation Inhibitors (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: